PROF · XBRL financial data

Profound Medical financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (PROF's year ends in late December)

In thousands of dollars	Q4 FY19Dec 31, 2019	Q4 FY20Dec 31, 2020	Q4 FY21Dec 31, 2021	Q4 FY22Dec 31, 2022	Q4 FY23Dec 31, 2023	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	—	—	—	—	year only	4,176*	2,621	2,211	5,289	5,977*	5,337	2,483
Revenue from contracts with customers	—	—	—	—	year only	4,026*	2,341	1,981	5,059	—	—	—
Cost of revenue	—	—	—	—	year only	1,214*	768	593	1,358	1,986*	1,505	536
Gross profit	—	—	—	—	year only	2,962*	1,853	1,618	3,931	3,991*	3,832	1,947
Research and development	—	—	—	—	year only	4,649*	4,808	6,098	5,418	4,272*	5,262	5,654
Selling, general and administrative	—	—	—	—	year only	6,658*	8,211	9,326	7,426	7,088*	6,591	7,359
Total operating expenses	—	—	—	—	year only	11,307*	13,019	15,424	12,844	11,360*	11,853	13,013
Operating income (loss)	—	—	—	—	year only	(8,345)*	(11,166)	(13,806)	(8,913)	(7,369)*	(8,021)	(11,066)
Interest expense	—	—	—	—	—	year only	104	86*	119*	85*	80	79*
Income tax expense (benefit)	—	—	—	—	year only	(238)*	41	64	121	26*	25	55
Net income (loss)	—	—	—	—	year only	(4,947)*	(10,724)	(15,695)	(7,977)	(8,175)*	(7,053)	(9,540)
Earnings per share, basic USD per share	—	—	—	—	—	—	0.36	0.52	0.26	—	0.19	(0.26)
Earnings per share, diluted USD per share	—	—	—	—	—	—	0.36	0.52	0.26	—	0.19	(0.26)
Weighted average shares, basic thousands of shares	—	—	—	—	—	25,782*	30,042	30,053	30,104	30,726*	36,298	36,351
Weighted average shares, diluted thousands of shares	—	—	—	—	—	25,782*	30,042	30,053	30,104	30,726*	36,298	36,351
Revenue	year only	year only	year only	year only	year only	—	—	—	—	—	—	—
Cost of sales	year only	year only	year only	year only	year only	—	—	—	—	—	—	—
Gross profit	year only	year only	year only	year only	year only	—	—	—	—	—	—	—
Research and development	year only	year only	year only	year only	year only	—	—	—	—	—	—	—
Operating profit (loss)	year only	year only	year only	year only	year only	—	—	—	—	—	—	—
Profit (loss)	year only	year only	year only	year only	year only	—	—	—	—	—	—	—

Balance sheet

CSV

Fiscal quarters (PROF's year ends in late December)

In thousands of dollars	Q4 FY19Dec 31, 2019	Q4 FY20Dec 31, 2020	Q4 FY21Dec 31, 2021	Q4 FY22Dec 31, 2022	Q4 FY23Dec 31, 2023	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	—	—	—	46,517	26,213	54,912	46,433	35,195	24,826	59,723	50,295	38,271
Inventory	—	—	—	—	6,989	5,801	6,795	8,353	8,337	8,238	9,001	10,456
Total current assets	—	—	—	—	41,896	69,065	59,912	48,811	41,524	76,089	69,530	58,864
Property and equipment, net	—	—	—	—	909	425	309	278	338	698	682	556
Right-of-use asset	—	—	—	—	661	396	342	303	240	184	2,897	2,763
Total assets	—	—	—	—	43,956	70,234	60,864	49,668	42,305	77,475	73,456	62,385
Accounts payable	—	—	—	—	865	1,317	1,048	949	717	1,563	2,142	955
Current portion of long-term debt	—	—	—	—	2,104	1,737	—	—	4,480	—	4,503	4,507
Total current liabilities	—	—	—	—	6,368	6,565	5,295	5,724	9,938	6,075	10,607	9,113
Long-term debt	—	—	—	—	5,000	2,924	4,486	4,462	—	4,499	—	—
Lease liability, non-current	—	—	—	—	504	203	136	72	—	—	2,892	2,754
Total liabilities	—	—	—	—	12,732	9,812	10,074	10,409	10,162	11,041	14,032	12,577
Accumulated deficit	—	—	—	—	(217,354)	(245,170)	(255,894)	(271,589)	(279,566)	(287,740)	(294,793)	(304,333)
Total stockholders' equity	—	—	—	52,597	31,224	60,422	50,790	39,259	32,143	66,434	59,424	49,808
Total liabilities and equity	—	—	—	—	43,956	70,234	60,864	49,668	42,305	77,475	73,456	62,385
Common shares outstanding (cover page) thousands of shares	11,853	20,209	20,776	20,879	21,371	30,040	30,053	30,053	30,194	36,294	36,338	36,533
Cash and cash equivalents	14,800	83,913	67,152	46,517	26,213	—	—	—	—	—	—	—
Total current assets	22,806	97,742	77,125	62,024	41,896	—	—	—	—	—	—	—
Total assets	30,060	104,601	86,775	64,421	43,911	—	—	—	—	—	—	—
Total current liabilities	8,224	4,809	4,155	4,185	6,366	—	—	—	—	—	—	—
Total liabilities	15,689	7,251	6,157	12,417	12,731	—	—	—	—	—	—	—
Total equity	14,371	97,350	80,618	52,004	31,180	—	—	—	—	—	—	—
Total equity and liabilities	30,060	104,601	86,775	64,421	43,911	—	—	—	—	—	—	—

Cash flows

CSV

Fiscal quarters (PROF's year ends in late December)

In thousands of dollars	Q4 FY19Dec 31, 2019	Q4 FY20Dec 31, 2020	Q4 FY21Dec 31, 2021	Q4 FY22Dec 31, 2022	Q4 FY23Dec 31, 2023	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	—	—	—	—	year only	(4,947)*	(10,724)	(15,695)	(7,977)	(8,175)*	(7,053)	(9,540)
Stock-based compensation	—	—	—	—	year only	442*	989	1,451*	1,669*	1,381*	1,048	874*
Net cash from operating activities	—	—	—	—	year only	(5,879)*	(8,283)	(13,744)*	(9,614)*	(6,566)*	(8,583)	(11,338)*
Purchases of property and equipment	—	—	—	—	—	—	—	—	—	year only	—	—
Net cash from investing activities	—	—	—	—	—	—	—	—	—	year only	—	—
Proceeds from issuing common stock	—	—	—	—	—	39,168*	—	—	—	year only	—	—
Repayments of long-term debt	—	—	—	—	year only	741*	290	0*	0*	0*	—	—
Net cash from financing activities	—	—	—	—	year only	35,435*	(290)	0*	0*	41,428*	—	—
Net cash from operating activities	year only	year only	year only	year only	year only	—	—	—	—	—	—	—
Net cash from investing activities	year only	year only	year only	—	—	—	—	—	—	—	—	—
Net cash from financing activities	year only	year only	year only	year only	year only	—	—	—	—	—	—	—

Compare with peers

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Profound Medical	38,271	2,483	(11,338)*	36.5M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Sight Sciences	79,753	23,388	(5,663)*	55.1M	14.1 quarters	Q2 FY26 10-QJun 30, 2026
Stereotaxis	10,491	7,670	(3,675)*	100.2M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
Sanara MedTech	15,421	28,137	2,038*	9.2M	—	Q2 FY26 10-QJun 30, 2026
Anika Therapeutics	38,412	32,610	(684)*	13.4M	56.2 quarters	Q2 FY26 10-QJun 30, 2026
SkinHealth Systems	206,074	72,113	2,671*	130.1M	—	Q2 FY26 10-QJun 30, 2026
AVITA Medical	9,139	21,702	(3,496)*	30.9M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
Utah Medical Products	87,528	8,529	1,383*	3.2M	—	Q2 FY26 10-QJun 30, 2026
Lakeland Industries	17,901	50,139	(404)*	9.9M	—	Q2 FY27 10-QJul 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.